← Back to list
OptimizeRx Medical Policy Update Effective 01/01/2027
Act
by Jan 1, 2027
Effective date
Jan 1, 2027
Identified
Oct 30, 2026
Summary
Blue Cross and Blue Shield of Nebraska (BCBSNE) is implementing a new step therapy requirement for Medical Policy X.242 OptimizeRX effective January 1, 2027. All preferred and non-preferred products will now require documented evidence of contraindication, intolerance, or inadequate response to a preferred product before coverage of a nonpreferred product is approved. This step therapy applies to both treatment-naïve and established patients, and preauthorization is required.
Get alerts when payers change rules like this one
We check Blue Cross Blue Shield of Nebraska and other payers every day and email you when a change matches your specialty and state.
Get Blue Cross Blue Shield of Nebraska alertsPolicy Monitoring is free. No card required.
What to do
by Jan 1, 2027 · 5 steps
01Billing and clinical staff must implement step therapy requirements for OptimizeRX (Medical Policy X.242) in BCBSNE claims processing.
02Before submitting claims for nonpreferred OptimizeRX products, obtain and document evidence of patient contraindication, intolerance, or inadequate response to a preferred product.
03Update prior authorization workflows to require this documentation for all patients (treatment-naïve and established).
04Ensure all claims for nonpreferred products include this clinical evidence or preauthorization will be denied by BCBSNE.
05Train front-desk, clinical, and billing staff on the new step therapy requirements to avoid claim denials.
Original notice
OptimizeRx Medical Policy Update Effective 01/01/2027
nebraskablue.com · Always check the source before changing claims.